Amicus Therapeutics (NASDAQ:FOLD) PT Raised to $20.00

Amicus Therapeutics (NASDAQ:FOLD) had its price objective hoisted by stock analysts at HC Wainwright from $18.00 to $20.00 in a research note issued to investors on Tuesday, Briefing.com Automated Import reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s target price would indicate a potential upside of 113.45% from the company’s previous close.

FOLD has been the topic of a number of other research reports. BidaskClub raised Amicus Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, November 5th. ValuEngine downgraded Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Friday. Cowen set a $31.00 target price on Amicus Therapeutics and gave the company a “buy” rating in a report on Thursday, October 10th. Zacks Investment Research raised Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $9.25 price objective on the stock in a report on Monday, November 4th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Amicus Therapeutics in a report on Thursday, October 17th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $17.97.

Shares of FOLD stock traded up $0.09 during trading hours on Tuesday, reaching $9.37. The company’s stock had a trading volume of 26,295 shares, compared to its average volume of 2,455,828. The firm’s 50 day simple moving average is $8.37 and its 200-day simple moving average is $10.84. The company has a market capitalization of $2.28 billion, a price-to-earnings ratio of -6.98 and a beta of 1.58. Amicus Therapeutics has a fifty-two week low of $7.11 and a fifty-two week high of $14.61. The company has a quick ratio of 6.97, a current ratio of 7.09 and a debt-to-equity ratio of 0.31.

Amicus Therapeutics (NASDAQ:FOLD) last issued its earnings results on Monday, November 11th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.32) by $0.08. The firm had revenue of $48.80 million for the quarter, compared to the consensus estimate of $48.05 million. Amicus Therapeutics had a negative return on equity of 66.79% and a negative net margin of 336.41%. The company’s revenue was up 136.9% compared to the same quarter last year. During the same quarter last year, the business posted ($0.84) EPS. Sell-side analysts predict that Amicus Therapeutics will post -1.38 earnings per share for the current year.

In related news, CEO John F. Crowley sold 14,500 shares of the firm’s stock in a transaction on Friday, October 11th. The stock was sold at an average price of $8.01, for a total transaction of $116,145.00. Following the completion of the transaction, the chief executive officer now directly owns 735,694 shares of the company’s stock, valued at approximately $5,892,908.94. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Burke W. Whitman bought 4,945 shares of the stock in a transaction that occurred on Friday, August 23rd. The shares were bought at an average cost of $10.07 per share, with a total value of $49,796.15. Following the completion of the transaction, the director now owns 21,612 shares in the company, valued at $217,632.84. The disclosure for this purchase can be found here. 2.50% of the stock is owned by company insiders.

Hedge funds have recently bought and sold shares of the company. Point72 Hong Kong Ltd bought a new position in shares of Amicus Therapeutics during the 2nd quarter worth approximately $49,000. US Bancorp DE increased its stake in Amicus Therapeutics by 50.9% during the 2nd quarter. US Bancorp DE now owns 4,896 shares of the biopharmaceutical company’s stock valued at $61,000 after purchasing an additional 1,651 shares in the last quarter. Meeder Asset Management Inc. acquired a new position in Amicus Therapeutics during the 2nd quarter valued at approximately $73,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. acquired a new position in Amicus Therapeutics during the 2nd quarter valued at approximately $122,000. Finally, Weil Company Inc. purchased a new stake in shares of Amicus Therapeutics in the 2nd quarter valued at $125,000.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.

Featured Article: What type of investment options does a Roth IRA provide?

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.